Melinda Magyari, MD, PhD, The Danish Multiple Sclerosis Center, Rigshospitalet, København, Denmark, discusses whether patients with multiple sclerosis (MS) have a greater risk for developing cancer. Dr Magyari highlights that it is important to understand if untreated MS patients are at an increased risk for developing cancer or if it is an adverse event of the disease-modifying treatments. Additionally, Dr Magyari defends that there is no evidence that MS is associated with a higher risk of cancer. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
Melinda Magyari has served on scientific advisory board for Biogen, Sanofi, Roche, Novartis, Merck, Abbvie, Alexion has received honoraria for lecturing from Biogen, Merck, Novartis, Sanofi, Genzyme, has received research support and support for congress participation from Biogen, Genzyme, Roche, Merck, Novartis.